Literature DB >> 22267339

Generation of a genomic reporter assay system for analysis of γ- and β-globin gene regulation.

Kasey S K Chan1, Jian Xu, Hady Wardan, Bradley McColl, Stuart Orkin, Jim Vadolas.   

Abstract

A greater understanding of the regulatory mechanisms that govern γ-globin expression in humans, especially the switching from γ- to β-globin, which occurs after birth, would help to identify new therapeutic targets for patients with β-hemoglobinopathy. To further elucidate the mechanisms involved in γ-globin expression, a novel fluorescent-based cellular reporter assay system was developed. Using homologous recombination, two reporter genes, DsRed and EGFP, were inserted into a 183-kb intact human β-globin locus under the control of (G)γ- or (A)γ-globin promoter and β-globin promoter, respectively. The modified constructs were stably transfected into adult murine erythroleukaemic (MEL) cells and human embryonic or fetal erythroleukemic (K562) cells, allowing for rapid and simultaneous analysis of fetal and adult globin gene expression according to their developmental stage-specific expression. To demonstrate the utility of this system, we performed RNA interference (RNAi)-mediated knockdown of BCL11A in the presence or absence of known fetal hemoglobin inducers and demonstrated functional derepression of a γ-globin-linked reporter in an adult erythroid environment. Our results demonstrate that the cellular assay system represents a promising approach to perform genetic and functional genomic studies to identify and evaluate key factors associated with γ-globin gene suppression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22267339      PMCID: PMC4050337          DOI: 10.1096/fj.11-199356

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  37 in total

1.  siDNMT1 increases γ-globin expression in chemical inducer of dimerization (CID)-dependent mouse βYAC bone marrow cells and in baboon erythroid progenitor cell cultures.

Authors:  Virryan Banzon; Vinzon Ibanez; Kestis Vaitkus; Maria Armila Ruiz; Kenneth Peterson; Joseph DeSimone; Donald Lavelle
Journal:  Exp Hematol       Date:  2010-10-23       Impact factor: 3.084

Review 2.  Control of fetal hemoglobin: new insights emerging from genomics and clinical implications.

Authors:  Swee Lay Thein; Stephan Menzel; Mark Lathrop; Chad Garner
Journal:  Hum Mol Genet       Date:  2009-10-15       Impact factor: 6.150

3.  The rationale for using hydroxycarbamide in the treatment of sickle cell disease.

Authors:  David C Rees
Journal:  Haematologica       Date:  2011-04       Impact factor: 9.941

4.  Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic β-type globin promoters in differentiated adult erythroid cells.

Authors:  Shuaiying Cui; Katarzyna E Kolodziej; Naoshi Obara; Alexandra Amaral-Psarris; Jeroen Demmers; Lihong Shi; James Douglas Engel; Frank Grosveld; John Strouboulis; Osamu Tanabe
Journal:  Mol Cell Biol       Date:  2011-06-13       Impact factor: 4.272

5.  Fetal globin expression is regulated by Friend of Prmt1.

Authors:  Thamar Bryn van Dijk; Nynke Gillemans; Farzin Pourfarzad; Kirsten van Lom; Marieke von Lindern; Frank Grosveld; Sjaak Philipsen
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

6.  Novel therapeutic candidates, identified by molecular modeling, induce γ-globin gene expression in vivo.

Authors:  Michael S Boosalis; Serguei A Castaneda; Marie Trudel; Rodwell Mabaera; Gary L White; Christopher H Lowrey; David W Emery; Marthe-Sandrine Eiymo Mwa Mpollo; Ling Shen; William A Wargin; Regine Bohacek; Douglas V Faller; Susan P Perrine
Journal:  Blood Cells Mol Dis       Date:  2011-08-15       Impact factor: 3.039

7.  Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.

Authors:  James E Bradner; Raymond Mak; Shyam K Tanguturi; Ralph Mazitschek; Stephen J Haggarty; Kenneth Ross; Cindy Y Chang; Jocelyn Bosco; Nathan West; Elizabeth Morse; Katherine Lin; John Paul Shen; Nicholas P Kwiatkowski; Nele Gheldof; Job Dekker; Daniel J DeAngelo; Steven A Carr; Stuart L Schreiber; Todd R Golub; Benjamin L Ebert
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

8.  Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer.

Authors:  Andrew Wilber; Phillip W Hargrove; Yoon-Sang Kim; Janice M Riberdy; Vijay G Sankaran; Eleni Papanikolaou; Maria Georgomanoli; Nicholas P Anagnou; Stuart H Orkin; Arthur W Nienhuis; Derek A Persons
Journal:  Blood       Date:  2010-12-14       Impact factor: 22.113

9.  Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin.

Authors:  Joseph Borg; Petros Papadopoulos; Marianthi Georgitsi; Laura Gutiérrez; Godfrey Grech; Pavlos Fanis; Marios Phylactides; Annemieke J M H Verkerk; Peter J van der Spek; Christian A Scerri; Wilhelmina Cassar; Ruth Galdies; Wilfred van Ijcken; Zeliha Ozgür; Nynke Gillemans; Jun Hou; Marisa Bugeja; Frank G Grosveld; Marieke von Lindern; Alex E Felice; George P Patrinos; Sjaak Philipsen
Journal:  Nat Genet       Date:  2010-08-01       Impact factor: 38.330

10.  Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease.

Authors:  Hassana Fathallah; Ali Taher; Ali Bazarbachi; George F Atweh
Journal:  Blood Cells Mol Dis       Date:  2009-04-05       Impact factor: 3.039

View more
  8 in total

1.  Transcriptional environment and chromatin architecture interplay dictates globin expression patterns of heterospecific hybrids derived from undifferentiated human embryonic stem cells or from their erythroid progeny.

Authors:  Kai-Hsin Chang; Andy Huang; Hemei Han; Yi Jiang; Xiangdong Fang; Chao-Zhong Song; Steve Padilla; Hao Wang; Hongzhu Qu; John Stamatoyannopoulos; Qiliang Li; Thalia Papayannopoulou
Journal:  Exp Hematol       Date:  2013-08-28       Impact factor: 3.084

Review 2.  Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders.

Authors:  Daniel E Bauer; Sophia C Kamran; Stuart H Orkin
Journal:  Blood       Date:  2012-08-17       Impact factor: 22.113

3.  Pharmacological Induction of Human Fetal Globin Gene in Hydroxyurea-Resistant Primary Adult Erythroid Cells.

Authors:  Yu-Chi Chou; Ruei-Lin Chen; Zheng-Sheng Lai; Jen-Shin Song; Yu-Sheng Chao; Che-Kun James Shen
Journal:  Mol Cell Biol       Date:  2015-05-18       Impact factor: 4.272

4.  Extensively self-renewing erythroblasts derived from transgenic β-yac mice is a novel model system for studying globin switching and erythroid maturation.

Authors:  Michael Getman; Samantha J England; Jeffery Malik; Kenneth Peterson; James Palis; Laurie A Steiner
Journal:  Exp Hematol       Date:  2014-04-02       Impact factor: 3.084

5.  A dual reporter mouse model of the human β-globin locus: applications and limitations.

Authors:  Petros Papadopoulos; Laura Gutiérrez; Reinier van der Linden; John Kong-A-San; Alex Maas; Dubravka Drabek; George P Patrinos; Sjaak Philipsen; Frank Grosveld
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

6.  Nuclease-mediated gene editing by homologous recombination of the human globin locus.

Authors:  Richard A Voit; Ayal Hendel; Shondra M Pruett-Miller; Matthew H Porteus
Journal:  Nucleic Acids Res       Date:  2013-10-23       Impact factor: 16.971

7.  Coordinated β-globin expression and α2-globin reduction in a multiplex lentiviral gene therapy vector for β-thalassemia.

Authors:  Tiwaporn Nualkaew; Karine Sii-Felice; Marie Giorgi; Bradley McColl; Julie Gouzil; Astrid Glaser; Hsiao P J Voon; Hsin Y Tee; George Grigoriadis; Saovaros Svasti; Suthat Fucharoen; Suradej Hongeng; Philippe Leboulch; Emmanuel Payen; Jim Vadolas
Journal:  Mol Ther       Date:  2021-05-01       Impact factor: 12.910

8.  A Novel High-Content Immunofluorescence Assay as a Tool to Identify at the Single Cell Level γ-Globin Inducing Compounds.

Authors:  Marta Durlak; Cristina Fugazza; Sudharshan Elangovan; Maria Giuseppina Marini; Maria Franca Marongiu; Paolo Moi; Ivan Fraietta; Paolo Cappella; Gloria Barbarani; Isaura Font-Monclus; Mario Mauri; Sergio Ottolenghi; Fabio Gasparri; Antonella Ronchi
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.